I)ESI~CSION 01: IICUADOI1EAN 1.AIION SYNUl<Ohlli GENII C'AI<I<II!I<S I%Y M0Lf:CULAR GENPrIC ANALYSIS 0l;GU'I'I II<Il:C,\I<I) HI-OOD SAMI'l.liS. h1.A Ili.1g.1 J. Gucv;lr;1-Agui11s,2 A.L. I <~~~c n l > l~~i l~l l .~;~~~~l LI. It is k n o w n that patients with Langerhans Cell Histiocytosis (LCH) are accompanied b y a variety of hypothalamtc-pitu~tary dysfunction (HPD). T o test the hypothesis that the endocrine abnormalities associated with L C H are related to the final h e~g h t , w e studied 4 5 patients with LCH. Twenty patients (5 boys a n d 1 5 girls) h a d been followed until they reached the final height. Observed clinical manifestations d u e to H P D were: diabetes insipidus in 11 p a t~e n t s , growth hormone d c f~c i e n c y In 6 patients, precocious puberty in 3 patients. A C T H d e l~c i e n c y in 6 patients a n d T S H deftciency in 2 patients. The mean S D score of body height of patients w a s n o t different from normal control at the onset of L C H However, the mean S D score of the f~n a l height of t h e patients w~t h L C H w a s significntly lower than normal control (-1.80+1.81; meankSD) The mean S D score of the final helght of the patients w~t h H P D (n=13) w a s s~g n i f~c a n t l y lower than the patients without H P D (n=7) ( -2 . 5 0 i 1 . 6 0 v s -0 5 9 i 1 . I . n,,,.,,,~, , 11. UCV gdm~,,~,,, 1 . I ,t1r8 ~s~a~, 11. I ,>rm,m, ,, 1 . I+,,,~~,.,,,,, n.n. .,,,I, I,,",, 88, 1 [l',,,l I. ,.), l',,,I,~,,, !, (1,,,81 ' , I , I ,I,, ,,#,,,,,,, (,,,,1/,11~, n,,l,Ll,,,,,,, I> Ill>" W.8. ,<,",I i i , , , l l y lilgl>(., lll_l, LO,I,~.UII (vtO.ull b, 111, 1. a1111 ,111, 1 1 ) ,. lLl, 1, ,,,,I,,,, Moderale to severe PHHI usually requlrcs ncar total pancreatcclomy to avo~d hypoglycemia Induced braln damage We treated 13 such patients w~th octrcolide over the last 6 y. Seven subsequently undcrwcnt partial pancrealectomy: 2 had ~nadeauate resoonse due l o seosls. 1 l a~l c d to resoond to combined octreoi~de/alucadon/d~azoxlde and 4'becausc thc~r familv sitbation d~d nnt nerm~l started lmmed~alely in 5 of 6 pat~ents slncc prcvious exper~erice lnd~cates that dlazox~de IS rarely ctlectlve in severe d~scase Octreotidc was glven In 3-4 daily sc ~nicct~ons In 3 oatienls. and continuous sc lnfusion (Mcd~x lnsulln lnluserl In 3. All pallents had aiute GI symptoms (vom~l~ng, abdom~nal d~stenlion, stcalorihea) and wcight loss alter beg~nn~ng the drug. Tills responded panlally to oral pancreatic enzyme treatment, and remitted alter 2-4 weeks. Asymptomat~c gallstoncs were dlscovcrcd at routlnc ultrasound In 1 patlent allcr 1 y ol Ircal~ncnl. Growth rate decreascd In all dur~ng the lirst 2-6 months, but normallzed subscqucnlly as d~d body we~ghl. All patients have normal psychomotor dcvcloplncnt lor age, howevcr 2 are <1 year old Every 6~1 2 montlls all atlcnlpl was ~nadc to stop oclruol~de treatment or sw~lch to d~azox~de. F~vc Datlents stooocd oclrcot~dc alter 8 5 m lo 5.5 avoided in some Dalients However, cll~cacv is oart~al, and close follow-uo w~th rcpcated blood glucose determinal~ons, lrcquent lied~ngs. gaslriislomy and llosp~tal admiss~ons durlng acute ~llnesses may still be ncccssary Most can cvcntually stop octreot~de and enter complete or partlal rcrnisslon. 
